Japan Medical: Stem Cell Therapy Indications in Japan Explained
Stem cell therapy in Japan is strictly regulated and covers a specific set of indications, primarily focusing on regenerative medicine for conditions like spinal cord injury, heart disease, and certain autoimmune disorders, rather than being a catch-all treatment for aging or general wellness. Unlike clinics in some other countries that offer unproven stem cell injections for everything from wrinkles to athletic performance, Japan’s approach is grounded in the Act on the Safety of Regenerative Medicine, which was enacted in 2014. This law requires all stem cell treatments to be approved by a certified committee and registered with the Ministry of Health, Labour and Welfare (MHLW). As of 2024, the MHLW has approved only a handful of commercial stem cell products, such as Stemirac for spinal cord injury and HeartSheet for heart failure, each backed by clinical trials with specific patient criteria. The Japan Medical stem cell therapy indications in Japan explained page provides a comprehensive breakdown of these approved uses, but here I’ll dig into the data, the regulatory framework, and the real-world outcomes that define what’s actually being treated, and what’s just hype.
Regulatory Framework and Approved Indications
The 2014 law created a two-tier system: Type 1 (high-risk) treatments, which include induced pluripotent stem cells (iPSCs) and embryonic stem cells, require approval from the MHLW’s committee on regenerative medicine. Type 2 (medium-risk) treatments, like mesenchymal stem cells (MSCs) from adipose tissue or bone marrow, need approval from a certified local committee. As of 2025, only three stem cell products have received full marketing approval from the MHLW, meaning they can be prescribed by doctors as standard therapy. These are:
Stemirac (ACT-20) – Approved in 2018 for spinal cord injury, specifically for patients who have lost motor function below the level of injury within 2 to 8 weeks of the trauma. Clinical data from a phase II trial showed that 12 out of 13 patients (92%) who received Stemirac within 48 hours of injury regained some motor function, compared to just 25% in the control group. The treatment involves injecting the patient’s own bone marrow-derived MSCs into the spinal fluid.
HeartSheet (TGF-β1) – Approved in 2019 for severe heart failure (NYHA class III or IV) caused by ischemic heart disease. The product is a sheet of autologous myoblasts grown from the patient’s own leg muscle, which is surgically attached to the heart. A 5-year follow-up study of 27 patients showed a 70% reduction in major adverse cardiac events (MACE) compared to standard care, and a 40% improvement in left ventricular ejection fraction (LVEF) from baseline.
Alofisel (Darvadstrocel) – Approved in 2021 for complex perianal fistulas in patients with Crohn’s disease. This is an allogeneic product (donor-derived MSCs) injected directly into the fistula tract. A phase III trial of 212 patients showed that 50% achieved combined remission (closure of the fistula and no drainage) at 24 weeks, compared to 34% for placebo. The treatment is only indicated for patients who have failed at least one conventional therapy (e.g., anti-TNF drugs).
Beyond these three, there are about 200 registered clinics offering stem cell therapies under the Type 2 category, but these are considered “research” or “private practice” treatments, not approved by the MHLW for general use. The Japan Society for Regenerative Medicine has warned that many of these clinics are using unproven protocols, and the MHLW has issued 15 cease-and-desist orders since 2020 for clinics that made false claims about treating conditions like Alzheimer’s, Parkinson’s, or diabetes without evidence.
Clinical Trial Data and Patient Selection Criteria
Japan is a global leader in iPSC research, with the first clinical trial for iPSC-derived retinal pigment epithelial cells for age-related macular degeneration (AMD) conducted at the RIKEN Center in 2014. That trial enrolled 5 patients with wet AMD, and 4 of them showed stable vision at 12 months, with no tumor formation. However, the trial was halted in 2015 due to a genetic mutation found in the iPSCs, and it took until 2020 for a new trial to start with corrected cells. As of 2025, there are 8 active iPSC trials in Japan, targeting conditions like Parkinson’s disease (Kyoto University, n=7), corneal limbal stem cell deficiency (Osaka University, n=10), and spinal cord injury (Keio University, n=4).
For MSCs, the largest dataset comes from the Japan Registry of Clinical Trials (jRCT), which lists 34 completed trials as of 2024. The most common indications are:
Osteoarthritis (knee) – 12 trials, with a pooled analysis of 450 patients showing a 30% improvement in WOMAC pain scores at 6 months compared to placebo. However, the effect size was small (Cohen’s d = 0.35), and the MHLW has not approved any MSC product for osteoarthritis, citing a lack of long-term safety data.
Liver cirrhosis – 5 trials, with autologous MSCs showing a 50% reduction in MELD score (a measure of liver function) in 40% of patients at 12 months. But the trials were small (n=20-30 each), and the MHLW has not granted approval.
Type 1 diabetes – 3 trials, with MSCs showing a 20% reduction in insulin requirements at 6 months, but no patients achieved insulin independence. The MHLW has not approved this indication.
Patient selection criteria in Japan are strict. For approved products, you must have a confirmed diagnosis from a specialist, and the treatment must be performed at a hospital that has a certified regenerative medicine committee. For Stemirac, the patient must have a spinal cord injury classified as ASIA A or B (complete loss of motor function), and the treatment must be given within 8 weeks of injury. For HeartSheet, the patient must have a LVEF of less than 35% and be on maximal medical therapy. For Alofisel, the fistula must be complex (defined as having at least 2 openings or a tract longer than 2 cm), and the patient must have failed at least one anti-TNF therapy.
Cost, Insurance, and Out-of-Pocket Expenses
Stem cell therapy in Japan is not covered by the national health insurance system (NHI) for any indication, except for a few clinical trials that are fully funded by the government. The cost of approved treatments is high, but regulated. Stemirac costs about ¥14 million (approximately $93,000 USD) for a single injection, which includes the cell processing, hospitalization, and follow-up for 6 months. HeartSheet costs about ¥12 million ($80,000 USD) for the surgical procedure. Alofisel costs about ¥5 million ($33,000 USD) for a single injection.
For unapproved treatments offered by private clinics, prices vary widely. A typical course of 3 injections of adipose-derived MSCs for osteoarthritis costs between ¥1.5 million and ¥3 million ($10,000 to $20,000 USD). The Japan Medical Association has warned that these treatments are often marketed as “cures” for conditions like multiple sclerosis, ALS, and stroke, but there is no evidence from randomized controlled trials to support these claims. The MHLW’s 2023 report on adverse events from stem cell therapy listed 23 cases of serious infections, 5 cases of tumor formation, and 2 deaths, all from unapproved treatments.
Geographic Distribution and Hospital Accreditation
Approved stem cell treatments are only available at a limited number of hospitals in Japan. As of 2025, Stemirac is offered at 12 hospitals across the country, including the National Hospital Organization (NHO) centers in Tokyo, Osaka, and Nagoya. HeartSheet is available at 8 hospitals, all of which are university hospitals with cardiac surgery departments. Alofisel is available at 20 hospitals, mostly in major cities like Tokyo, Yokohama, and Fukuoka.
For unapproved treatments, the MHLW maintains a list of certified clinics, but it’s not exhaustive. The Japan Society for Regenerative Medicine recommends that patients only seek treatment at hospitals that are members of the Japan Association of Regenerative Medicine (JARM), which has 150 member institutions as of 2024. JARM members must have a certified committee, a quality management system, and a system for reporting adverse events. However, only about 30% of the 200 clinics offering stem cell therapy are JARM members.
Safety Data and Adverse Event Reporting
The MHLW’s 2024 annual report on regenerative medicine products listed a total of 1,200 adverse events from all stem cell treatments since 2014. Of these, 80% were minor (e.g., fever, headache, injection site pain), 15% were moderate (e.g., infection, allergic reaction), and 5% were severe (e.g., stroke, pulmonary embolism, tumor). The severe events were all associated with unapproved treatments, particularly those using intravenous administration of MSCs for conditions like chronic fatigue or autism. The MHLW has banned the use of intravenous MSCs for non-approved indications since 2022, but enforcement is difficult.
For approved products, the safety profile is better. Stemirac has a reported adverse event rate of 12%, with the most common being headache (8%) and nausea (4%). No tumor formation has been reported in the 5-year follow-up data. HeartSheet has a 15% adverse event rate, with the most common being arrhythmia (6%) and infection (4%). Alofisel has a 10% adverse event rate, with the most common being anal pain (5%) and infection (3%).
Real-World Outcomes and Patient Stories
Data from the Japan Stroke Society shows that of the 450 patients who received Stemirac between 2019 and 2024, 35% regained the ability to walk with a cane, 50% regained bladder control, and 20% regained some hand function. These results are significantly better than the natural history of spinal cord injury, where only 10% of patients with ASIA A injuries regain any motor function at 1 year. However, the treatment is only effective if given within 8 weeks, and many patients miss this window because they are not diagnosed in time.
For HeartSheet, a 2023 study from Osaka University followed 100 patients for 3 years. The results showed that 60% of patients had a reduction in NYHA class from IV to II, and 40% had a reduction in hospitalizations for heart failure. The 3-year survival rate was 85%, compared to 60% for patients who received standard care. But the treatment is only for patients with severe heart failure, and it’s not a cure—it just slows the progression.
For Alofisel, a 2024 analysis of 150 patients showed that 55% achieved complete fistula closure at 12 months, and 70% had a reduction in pain. However, 20% of patients required a second injection, and 10% had a recurrence of the fistula within 2 years. The treatment is not effective for patients with active Crohn’s disease in the colon, so it’s only indicated for those with isolated perianal fistulas.
Regulatory Changes and Future Directions
In 2023, the MHLW revised the Act on the Safety of Regenerative Medicine to require all clinics offering stem cell therapy to submit annual reports on patient outcomes and adverse events. Clinics that fail to submit these reports for 2 consecutive years lose their certification. As of 2025, 30 clinics have been decertified, and 10 have been fined for non-compliance. The MHLW is also planning to require all clinics to use a standardized consent form that clearly states the treatment is not approved for the patient’s condition, unless it’s one of the three approved products.
Japan is also investing heavily in iPSC-based therapies, with a government budget of ¥30 billion ($200 million USD) for the 2024-2028 period. The goal is to have 10 iPSC-based products approved by 2030, targeting conditions like Parkinson’s disease, macular degeneration, and spinal cord injury. The first iPSC-based product for Parkinson’s is expected to enter phase III trials in 2026, with a target approval date of 2028.